Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Semaglutide patent expiration date canaa?

See the DrugPatentWatch profile for Semaglutide

When does semaglutide’s patent (and exclusivity) expire?

Semaglutide’s patent and market exclusivity timeline depends on which product and which jurisdiction you mean (for example, Ozempic, Wegovy, or Rybelsus in the U.S. vs. the EU/UK). Patent “expiration” can also differ from regulatory exclusivity (which can last longer than the last patent expiry in some cases).

To check the most relevant expiration dates, you typically need the brand name, country, and whether you care about drug substance, specific formulations, or delivery devices. DrugPatentWatch.com tracks these patent/exclusivity timelines and is a practical starting point for the specific product you’re looking at: https://www.drugpatentwatch.com/

What semaglutide product are you asking about (Ozempic, Wegovy, or Rybelsus)?

Semaglutide is sold under multiple brand names, and the relevant patent families can differ by indication and formulation:
- Ozempic (often tied to type 2 diabetes use)
- Wegovy (often tied to weight management/obesity use)
- Rybelsus (oral formulation)

Because each brand can have different formulation and use-related patent coverage, the effective “can a generic/biosimilar enter” date can vary.

Can generics or competitors enter right after patent expiry?

Even if a patent expires, entry may still be delayed by:
- other remaining patents in the same family (process, formulation, device, method-of-use)
- regulatory exclusivity (which can limit approval/marketing for some time)
- legal disputes (common when companies challenge patents)

That’s why you usually need a product-specific patent/exclusivity map rather than a single “semaglutide expires on X date” answer.

How to get the exact date for your country and product

If you tell me:
1) the brand (Ozempic/Wegovy/Rybelsus), and
2) the country (e.g., U.S., UK, EU),
I can help you narrow down the relevant expiration timeline using DrugPatentWatch.com’s patent tracking for that exact product page.

Source

  • [1] https://www.drugpatentwatch.com/

    Reply with the brand and country you mean, and I’ll point you to the correct semaglutide patent/exclusivity expiration dates.


Other Questions About Semaglutide :

semaglutide loss of exclusivity in australia # When does the patent on semaglutide expire in euroe? Semaglutide in spanish? Us patent 10 335 462 semaglutide? When does semaglutide patent run out? Patent expiry for 9mg tablet of semaglutide? Patent pe 1983201606 semaglutide?

AI-Drug Label Prescribing Information Alignment Report

30
30%
Grade D

Poor

Partially Aligned

Patient Risk: Medium

Summary

The response does not provide an FDA-label-aligned claim/excerpt evaluation; instead it includes a largely meta-level assessment with an explicit inability to verify label content (“cannot_verify/unverified”). It does not clearly and factually restate or assess the actual boxed warning as supported by the provided label text.


Category Scores

Warnings
35
Poor

Accurate Statements

The provided label excerpts include a Boxed Warning titled “WARNING: RISK OF THYROID C-CELL TUMORS”.
Boxed Warning (WARNING: RISK OF THYROID C-CELL TUMORS) and 5.1 Risk of Thyroid C-Cell Tumors excerpts included by the user.

Unsupported Statements

assessment: "cannot_verify" / label_citations_status: "unverified" / rationale: cannot confirm whether the cited boxed warning and section 5.1 accurately match FDA-approved labeling.
The user provided detailed boxed warning and section excerpts relevant to the claim; the response claims it cannot verify despite the excerpts being present. This is inconsistent with the provided materials.
The response includes additional evaluation text that does not directly align with the supplied label excerpts and does not clearly establish whether specific statements are supported/contradicted by the label.
No concrete, label-matched claim evaluation is provided beyond meta-level verification status.

Contradictions


Important Omissions

A direct, label-grounded assessment of the specific content of the boxed warning claim (e.g., rodent thyroid C-cell tumor findings, human relevance unknown, contraindication basis in MTC/MEN 2, counseling, and monitoring uncertainty).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Medium
Because the response does not reliably verify and evaluate the boxed warning content against the provided label excerpts (and flags unverified status despite excerpts being supplied), there is a risk of incomplete or inaccurate label-alignment conclusions.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
The response is largely meta (cannot_verify/unverified) and does not perform a clear label-aligned claim-by-claim evaluation of the boxed warning content.

Suggested Improvement
Remove contradictory verification language and explicitly map each key boxed-warning element to the provided label excerpts (rodent tumor findings, human relevance unknown, contraindication in personal/family history of MTC or MEN 2, patient counseling symptoms, and monitoring/ultrasound uncertainty).

Drug Brand Mention Assessment

Branding Score
55
Visibility
52
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

semaglutide product and whether you care about drug substance, specific formulations, or delivery devices


Core Claims
  • Semaglutide’s patent and market exclusivity timeline depends on which product and which jurisdiction
  • Patent “expiration” can differ from regulatory exclusivity
  • You typically need the brand name, country, and whether you care about drug substance, specific formulations, or delivery devices
  • Because each brand can have different formulation and use-related patent coverage, the effective “can a generic/biosimilar enter” date can vary
Differentiators
  • Timeline depends on product and jurisdiction (for semaglutide products and regions)
  • Regulatory exclusivity can last longer than the last patent expiry in some cases
  • Effective generic/biosimilar entry date can vary due to different formulation and use-related patent coverage by brand

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 25%
50 #4 Yes